Isis Licenses Antisense Tools to Merck

Feb 21, 2002

NEW YORK, Feb. 21 - Isis Pharmaceuticals has struck a deal with Merck to provide the pharmaceutical giant with antisense tools for drug-target validation, the company said on Thursday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Already have an account?
Login Now.

Breaking News

CMS 2018 Preliminary PAMA Pricing Not Market Based, Lab Group Says
FDA Approves Merck's Keytruda, Agilent Dako CDx for Gastric Cancer Indications
In Brief This Week: Agilent, Edico Genome, Alere, and More
White Guinea Yam Genome Sequence Offers Insight Into Dioecy Plants
Signature Science Wins $2.9M IARPA Contract for Biological Threat Detection Computational Tools
People in the News: Olivier Elemento, Andrew Witty, Michael Korn, More

The Scan

Mouse Fight

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Seeing the Interactions

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

This Week in Science

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

For Millions

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.

Main menu